Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TEST TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT
6 REGULATORY FRAMEWORK
6.1 REGULATORY SCENARIO IN THE U.S
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING INCIDENCE OF BLADDER CANCER NORTH AMERICALY
7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER
7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY
7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER
7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES
7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS
7.3 OPPORTUNITIES
7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS
7.3.3 INCREASE IN THE GERIATRIC POPULATION
7.4 CHALLENGES
7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING
7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES
8 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 CYSTOSCOPY
8.3 URINE LAB TEST
8.3.1 URINE CYTOLOGY
8.3.2 URINALYSIS
8.3.3 URINE TUMOR MARKER TEST
8.3.4 URINE CULTURE
8.3.5 OTHERS
8.4 BIOPSY
8.5 IMAGING TEST
8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN
8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN
8.5.3 ULTRASOUND
8.5.4 INTRAVENOUS PYELOGRAM (IVP)
8.6 OTHERS
9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES
9.1 OVERVIEW
9.2 STAGE IV
9.3 STAGE III
9.4 STAGE II
9.5 STAGE I
10 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 TRANSITIONAL CELL BLADDER CANCER
10.3 SQUAMOUS CELL BLADDER CANCER
10.4 OTHER CANCER TYPES
11 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITAL
11.3 DIAGNOSTIC IMAGING CENTERS
11.4 CANCER RESEARCH INSTITUTES
11.5 INDEPENDENT DIAGNOSTIC LABORATORIES
11.6 ASSOCIATED LABS
12 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET
16.1 F. HOFFMANN- LA ROCHE LTD
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 MERCK KGAA
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 THERMO FISHER SCIENTIFIC INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 KONINLIJKE PHILIPS N.V.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 BIO-RAD LABORATORIES, INC.
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SNAPSHOT
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ABBOTT
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 AGILENT TECHNOLOGIES, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 AMBU A/S
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BD
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 CANON MEDICAL SYSTEMS CORPORATION
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 FUJIFILM CORPORATION
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 GENERAL ELECTRIC COMPANY
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENTS
16.14 HOLOGIC INC.
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 ILLUMINA INC
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 MINFOUND MEDICAL SYSTEMS CO.,
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 NEUSOFT CORPORATION
16.17.1 COMPANY SNAPSHOT
16.17.2 COMPANY SNAPSHOT
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.18 QIAGEN
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENT
16.19 SIEMENS HEALTHCARE GMBH
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 TIME MEDICAL HOLDING.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA CYSTOSCOPY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA BIOPSY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA OTHERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA STAGE IV IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA STAGE III IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA STAGE II IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA STAGE I IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA TRANSITIONAL CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA SQUAMOUS CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA OTHER CANCER TYPES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA HOSPITAL IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA DIAGNOSTIC IMAGING CENTERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA CANCER RESEARCH INSTITUTES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA ASSOCIATED LABS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA DIRECT TENDER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA RETAIL SALES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 35 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 36 U.S. URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 37 U.S. IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 39 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 40 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 41 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 42 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 43 CANADA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 CANADA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 45 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 46 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 47 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 49 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 MEXICO URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 51 MEXICO IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 52 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 53 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 54 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 55 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF BLADDER CANCER NORTH AMERICALY IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 CYSTOSCOPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 15 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2022
FIGURE 19 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 22 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 23 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 35 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 36 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 39 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
